Efficacy of 2.5% Pimafucin suspension in the treatment of denture stomatitis.
This double-blind clinical trial was carried out in 38 patients to compare the efficacy of 2.5% Pimafucin suspension with a placebo in the treatment of denture stomatitis. The diagnosis of Candida infection was confirmed by the making of cultures and microscopic examination. Data were analyzed from 32 patients, of whom 18 received Pimafucin suspension and 14 a placebo suspension. Pimafucin suspension-treated patients showed a significant reduction of Candida infection in terms of culture, culture growth, and number of colonies within the first week of therapy. There was no statistical evidence of relapse during the 4-week period after therapy was stopped. The group receiving a placebo failed to show any statistically significant improvement with respect to the mentioned parameters. Erythema of oral mucosa showed significant improvement in both groups. No side effects were found.
D000328:Adult; D000368:Aged; D002180:Candidiasis, Oral / Q000188:drug therapy*; D003824:Denture, Complete / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010866:Natamycin / Q000627:therapeutic use*; D010919:Placebos; D013280:Stomatitis / Q000188:drug therapy*; D013282:Stomatitis, Denture / Q000188:drug therapy* / Q000382:microbiology; D013997:Time Factors
D010919:Placebos; D010866:Natamycin